APP

APP encodes the amyloid precursor protein, a core gene in an Alzheimer’s disease-associated module and a putative mechanistic node in a network centered on APP, JUN, and PPARγ. It is best known for its role in amyloid processing, making it relevant to alzheimers disease and other neurodegenerative pathways. The literature highlights APP as a target for gene editing, including crispr cas9-based strategies aimed at precisely modulating APP-associated pathways. Disease models have included human and rat systems carrying Swedish/London or Swedish/Indiana APP mutations, linking APP variants to progressive mitochondrial dysfunction and cerebral amyloidosis. Overall, APP is positioned as a mechanistically important node in AD biology, with recent work spanning network-pharmacology, gene-editing, and in vitro/in vivo modeling.

Alzheimer’s disease

  • APP was identified as a core gene in an AD-associated gene module from a network-pharmacology analysis of seahorse compounds, supporting its central role in disease-relevant signaling (PMID:41922822).
  • A 2026 review discussed APP as a target for gene editing to modulate amyloid processing in Alzheimer’s disease, emphasizing therapeutic pathway control rather than direct replacement (PMID:41931258).
  • CRISPR-Cas9 and next-generation gene-editing approaches were highlighted as strategies to precisely modulate APP-associated pathways in AD (PMID:41931258).
  • Human and rodent models carrying Swedish/London or Swedish/Indiana APP mutations were used to study progressive mitochondrial dysfunction as an early event in cerebral amyloidosis (PMID:41637762).

Mechanistic and model systems

  • APP was described as part of a core module centered on APP, JUN, and PPARγ, indicating a broader mechanistic network beyond amyloid biology (PMID:41922822).
  • The mutation-bearing APP models in both human in vitro and rodent in vivo systems provide translational support for studying amyloidogenic processing and downstream mitochondrial effects (PMID:41637762).
  • The seahorse-compound study integrated ethnopharmacology, bioactivity, bibliometrics, and network pharmacology to prioritize APP-linked AD mechanisms (PMID:41922822).